查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1675295

2025 年至 2033 年罕见血液疾病治疗市场报告（按疗法、疾病适应症、配销通路和地区划分）

Acquired Orphan Blood Diseases Therapeutics Market Report by Therapy, Disease Indication, Distribution Channel, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 137 Pages | 商品交期: 2-3个工作天内

价格

2024IMARC Group全球获得性孤儿血液疾病治疗市场规模达到 95 亿美元。罕见血液疾病诊断率的上升、基因治疗和生物製剂的进步、政府透过孤儿药指定和监管激励措施提供的支持不断增加、人们对这些疾病的认识不断提高以及治疗效果的提高是推动市场成长的一些主要因素。

后天性孤儿血病是一种罕见的血液疾病，因无法产生红血球 (RBC) 或血液中红血球不足而引起。它们包括多种疾病，例如骨髓增生异常综合症 (MDS)、特发性血小板减少性紫斑症 (ITP)、阵发性睡眠性血红蛋白尿 (PNH)、骨髓纤维化 (MF)、真性红血球增多症 (PV) 和后天性粒细胞缺乏症。它们会导致骨髓功能异常并减少血小板数量。由于它们可以透过重组因子、免疫球蛋白输注疗法、活化凝血酶原复合物浓缩物和血小板生成素受体激动剂等多种疗法进行治疗，因此全球对获得性孤儿血液疾病治疗药物的需求正在上升。

后天性孤儿血液疾病治疗市场趋势：

目前，大众对血液疾病及其治疗方案认知的不断提高，以及全球个人收入水准的不断提高，是积极影响市场的主要因素之一。此外，由于老年人口的增加，对血液疾病治疗选择的需求不断增加，这也促进了市场的成长。与此相符的是，各国的管理机构和私人组织正在透过在个人中传播有关血液相关疾病发生的认识来鼓励采用血液疾病治疗方法，并在世界各地提供多项医疗保健倡议，推动市场的成长。除此之外，由于全球各种血液相关疾病的发生率不断上升，血液疾病治疗的采用也日益广泛，这为市场带来了积极的前景。此外，透过世界各地的线上和线下药局广泛供应的孤儿血液疾病治疗药物也促进了市场的成长。除此之外，个人对个人化医疗的需求不断增长，以及全球医疗保健基础设施的改善，为行业投资者提供了丰厚的成长机会。除此之外，全球个人对具有成本效益和高品质护理解决方案的需求也在增加。再加上人们越来越多地采用预防性护理和保健服务以避免个人之间疾病的广泛传播，这些都促进了市场的成长。此外，主要製造商正在为患有镰状细胞性贫血的儿科患者引入基于羟基脲的治疗方法，这支持了市场的成长。

本报告回答的关键问题：

  • 全球获得性孤儿血液疾病治疗市场迄今表现如何？
  • 全球获得性孤儿血液疾病治疗市场的驱动因素、限制因素和机会有哪些？
  • 每个驱动因素、限制因素和机会对全球获得性孤儿血液疾病治疗市场有何影响？
  • 主要的区域市场有哪些？
  • 哪些国家拥有最具吸引力的后天孤儿血液疾病治疗市场？
  • 根据治疗方法，市场区隔如何？
  • 在获得性孤儿血液疾病治疗市场中哪种疗法最具吸引力？
  • 根据疾病指征，市场如何划分？
  • 在后天性孤儿血液疾病治疗市场中，哪种疾病适应症最具吸引力？
  • 根据配销通路，市场如何划分？
  • 在获得性孤儿血液疾病治疗市场中，哪个配销通路最具吸引力？
  • 市场的竞争格局是怎么样的？
  • 全球获得性孤儿血液疾病治疗市场的主要参与者/公司有哪些？

目录

第 1 章：前言

第 2 章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球获得性孤儿血液疾病治疗市场

  • 市场概况
  • 市场表现
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依疗法

  • 重组因子
  • 免疫球蛋白输注治疗
  • 活性凝血酶原复合物浓缩物
  • 血小板生成素受体激动剂
  • 其他的

第七章：市场区隔：依疾病适应症

  • 后天性粒细胞缺乏症
  • 后天性血友病
  • 后天性血管性血友病症候群
  • 阵发性睡眠性血红素尿症 (PNH)
  • 骨髓造血不良症候群
  • 其他的

第 8 章：市场区隔：按配销通路

  • 医院药房
  • 零售药局
  • 其他的

第九章：市场细分：依地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场区隔：依国家

第 10 章：驱动因素、限制因素与机会

  • 概述
  • 驱动程式
  • 限制
  • 机会

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 13 章：价格分析

第 14 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Alexion Pharmaceuticals Inc. (AstraZeneca plc)
    • Amgen Inc.
    • GSK plc
    • Novartis AG
    • Novo Nordisk A/S
    • Otsuka Pharmaceutical Co. Ltd.
    • Rigel Pharmaceuticals Inc.
    • Roche Holding AG
    • Sanofi
    • Takeda Pharmaceutical Company Limited
Product Code: SR112025A8217

The global acquired orphan blood diseases therapeutics market size reached USD 9.5 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 18.1 Billion by 2033, exhibiting a growth rate (CAGR) of 7.13% during 2025-2033. The increasing diagnosis rates of rare blood disorders, advancements in gene therapy and biologics, growing government support through orphan drug designations and regulatory incentives, the rising awareness of these conditions, and improvements in treatment efficacy are some of the major factors propelling the market growth.

Acquired orphan blood diseases are rare blood conditions that are caused by an inability to produce red blood cells (RBCs) or their insufficiency in the blood. They comprise numerous diseases, such as myelodysplastic syndrome (MDS), idiopathic thrombocytopenic purpura (ITP), paroxysmal nocturnal hemoglobinuria (PNH), myelofibrosis (MF), polycythemia vera (PV), and acquired agranulocytosis. They can cause improper functioning of bone marrow and can decrease the number of platelets. As they can be treated through several therapies, such as recombinant factor, immunoglobulin infusion therapy, activated prothrombin complex concentrate, and thrombopoietin receptor agonists, the demand for acquired orphan blood disease therapeutics is rising across the globe.

Acquired Orphan Blood Diseases Therapeutics Market Trends:

At present, the increasing awareness about blood diseases and their treatment options among the masses, along with the inflating income level of individuals worldwide, represents one of the major factors influencing the market positively. Moreover, the rising demand for blood disease therapeutics options due to the increasing geriatric population is strengthening the growth of the market. In line with this, governing agencies and private organizations of various countries are encouraging the adoption of blood disease therapeutics by spreading awareness about the occurrence of blood-associated disorders among individuals and offering several healthcare initiatives around the world is impelling the growth of the market. Apart from this, the growing adoption of blood disease therapeutics due to the increasing prevalence of various blood-related disorders among individuals across the globe is offering a positive market outlook. Additionally, the wide availability of acquired orphan blood disease therapeutics drugs through online and offline pharmacy stores around the world is contributing to the growth of the market. Besides this, the increasing demand for personalized medicines among individuals, along with the improving healthcare infrastructure worldwide, is offering lucrative growth opportunities to industry investors. In addition to this, there is a rise in the demand for cost-effective and quality care solutions among individuals across the globe. This, coupled with the increasing adoption of preventative care and wellness services to avoid widespread disease among individuals, is bolstering the growth of the market. Furthermore, key manufacturers are introducing hydroxyurea-based treatment for pediatric patients with sickle cell anemia, which is supporting the growth of the market.

Key Market Segmentation:

Therapy Insights:

  • Recombinant Factor
  • Immunoglobulin Infusion Therapy
  • Activated Prothrombin Complex Concentrate
  • Thrombopoietin Receptor Agonists
  • Others

Disease Indication Insights:

  • Acquired Agranulocytosis
  • Acquired Hemophilia
  • Acquired Von Willebrand Syndrome
  • Paroxysmal Nocturnal Hemoglobinuria (PNH)
  • Myelodysplastic Syndrome
  • Others

Distribution Channel Insights:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

Regional Insights:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa
  • The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for acquired orphan blood diseases therapeutics. Some of the factors driving the North America acquired orphan blood diseases therapeutics market included the growing awareness about several treatment options, wide availability of therapeutic drugs, favorable government initiatives, etc.

Competitive Landscape:

  • The report has also provided a comprehensive analysis of the competitive landscape in the global acquired orphan blood diseases therapeutics market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Alexion Pharmaceuticals Inc. (AstraZeneca plc), Amgen Inc., GSK plc, Novartis AG, Novo Nordisk A/S, Otsuka Pharmaceutical Co. Ltd., Rigel Pharmaceuticals Inc., Roche Holding AG, Sanofi, Takeda Pharmaceutical Company Limited, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

  • How has the global acquired orphan blood diseases therapeutics market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global acquired orphan blood diseases therapeutics market?
  • What is the impact of each driver, restraint, and opportunity on the global acquired orphan blood diseases therapeutics market?
  • What are the key regional markets?
  • Which countries represent the most attractive acquired orphan blood diseases therapeutics market?
  • What is the breakup of the market based on the therapy?
  • Which is the most attractive therapy in the acquired orphan blood diseases therapeutics market?
  • What is the breakup of the market based on the disease indication?
  • Which is the most attractive disease indication in the acquired orphan blood diseases therapeutics market?
  • What is the breakup of the market based on the distribution channel?
  • Which is the most attractive distribution channel in the acquired orphan blood diseases therapeutics market?
  • What is the competitive structure of the market?
  • Who are the key players/companies in the global acquired orphan blood diseases therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Acquired Orphan Blood Diseases Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Therapy

  • 6.1 Recombinant Factor
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Immunoglobulin Infusion Therapy
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Activated Prothrombin Complex Concentrate
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Thrombopoietin Receptor Agonists
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Disease Indication

  • 7.1 Acquired Agranulocytosis
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Acquired Hemophilia
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Acquired Von Willebrand Syndrome
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Paroxysmal Nocturnal Hemoglobinuria (PNH)
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Myelodysplastic Syndrome
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacy
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Retail Pharmacy
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Alexion Pharmaceuticals Inc. (AstraZeneca plc)
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Amgen Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 GSK plc
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Novartis AG
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Novo Nordisk A/S
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Otsuka Pharmaceutical Co. Ltd.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7 Rigel Pharmaceuticals Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Roche Holding AG
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
    • 14.3.9 Sanofi
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Takeda Pharmaceutical Company Limited
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

List of Figures

  • Figure 1: Global: Acquired Orphan Blood Diseases Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Acquired Orphan Blood Diseases Therapeutics Market: Breakup by Therapy (in %), 2024
  • Figure 5: Global: Acquired Orphan Blood Diseases Therapeutics Market: Breakup by Disease Indication (in %), 2024
  • Figure 6: Global: Acquired Orphan Blood Diseases Therapeutics Market: Breakup by Distribution Channel (in %), 2024
  • Figure 7: Global: Acquired Orphan Blood Diseases Therapeutics Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Acquired Orphan Blood Diseases Therapeutics (Recombinant Factor) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Acquired Orphan Blood Diseases Therapeutics (Recombinant Factor) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Acquired Orphan Blood Diseases Therapeutics (Immunoglobulin Infusion Therapy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Acquired Orphan Blood Diseases Therapeutics (Immunoglobulin Infusion Therapy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Acquired Orphan Blood Diseases Therapeutics (Activated Prothrombin Complex Concentrate) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Acquired Orphan Blood Diseases Therapeutics (Activated Prothrombin Complex Concentrate) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Acquired Orphan Blood Diseases Therapeutics (Thrombopoietin Receptor Agonists) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Acquired Orphan Blood Diseases Therapeutics (Thrombopoietin Receptor Agonists) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Acquired Orphan Blood Diseases Therapeutics (Other Therapies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Acquired Orphan Blood Diseases Therapeutics (Other Therapies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Acquired Orphan Blood Diseases Therapeutics (Acquired Agranulocytosis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Acquired Orphan Blood Diseases Therapeutics (Acquired Agranulocytosis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Acquired Orphan Blood Diseases Therapeutics (Acquired Hemophilia) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Acquired Orphan Blood Diseases Therapeutics (Acquired Hemophilia) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Acquired Orphan Blood Diseases Therapeutics (Acquired Von Willebrand Syndrome) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Acquired Orphan Blood Diseases Therapeutics (Acquired Von Willebrand Syndrome) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Acquired Orphan Blood Diseases Therapeutics (Paroxysmal Nocturnal Hemoglobinuria (PNH)) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Acquired Orphan Blood Diseases Therapeutics (Paroxysmal Nocturnal Hemoglobinuria (PNH)) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Acquired Orphan Blood Diseases Therapeutics (Myelodysplastic Syndrome) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Acquired Orphan Blood Diseases Therapeutics (Myelodysplastic Syndrome) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: Acquired Orphan Blood Diseases Therapeutics (Other Disease Indications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: Acquired Orphan Blood Diseases Therapeutics (Other Disease Indications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Global: Acquired Orphan Blood Diseases Therapeutics (Hospital Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Global: Acquired Orphan Blood Diseases Therapeutics (Hospital Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Global: Acquired Orphan Blood Diseases Therapeutics (Retail Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Global: Acquired Orphan Blood Diseases Therapeutics (Retail Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Global: Acquired Orphan Blood Diseases Therapeutics (Other Distribution Channels) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Global: Acquired Orphan Blood Diseases Therapeutics (Other Distribution Channels) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: North America: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: North America: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: United States: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: United States: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: Canada: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: Canada: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: Asia-Pacific: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: Asia-Pacific: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: China: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: China: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Japan: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Japan: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: India: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: India: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: South Korea: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: South Korea: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Australia: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Australia: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: Indonesia: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: Indonesia: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Others: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Others: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Europe: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Europe: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Germany: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Germany: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: France: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: France: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: United Kingdom: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: United Kingdom: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Italy: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Italy: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Spain: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Spain: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Russia: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Russia: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Others: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Others: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Latin America: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Latin America: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: Brazil: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 77: Brazil: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 78: Mexico: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 79: Mexico: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 80: Others: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 81: Others: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 82: Middle East and Africa: Acquired Orphan Blood Diseases Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 83: Middle East and Africa: Acquired Orphan Blood Diseases Therapeutics Market: Breakup by Country (in %), 2024
  • Figure 84: Middle East and Africa: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 85: Global: Acquired Orphan Blood Diseases Therapeutics Industry: Drivers, Restraints, and Opportunities
  • Figure 86: Global: Acquired Orphan Blood Diseases Therapeutics Industry: Value Chain Analysis
  • Figure 87: Global: Acquired Orphan Blood Diseases Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Acquired Orphan Blood Diseases Therapeutics Market: Key Industry Highlights, 2024 & 2033
  • Table 2: Global: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Breakup by Therapy (in Million USD), 2025-2033
  • Table 3: Global: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Breakup by Disease Indication (in Million USD), 2025-2033
  • Table 4: Global: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 5: Global: Acquired Orphan Blood Diseases Therapeutics Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Acquired Orphan Blood Diseases Therapeutics Market: Competitive Structure